Wilson Sonsini Goodrich & Rosati advised RA Capital Management on the deal. Rivus Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to improving cardio-metabolic health, announced the completion...
Rivus Pharmaceuticals’ $132 Million Series B Financing
Boston Scientific’s Acquisition of Obsidio
Wilson Sonsini Goodrich & Rosati advised Obsidio on the deal, while Latham & Watkins represented Boston Scientific Corporation. Boston Scientific Corporation announced the acquisition of Obsidio, Inc.,...
Novartis’ Acquisition of Kedalion Therapeutics
Wilson Sonsini advised Kedalion Therapeutics on the deal. Novartis announced that it acquired Kedalion Therapeutics and its AcuStream technology, an innovative device that may have the...
Apexigen’s Business Combination Agreement with Brookline Capital Acquisition Corp.
Wilson Sonsini advised Apexigen on the deal. Apexigen, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing a new generation of antibody therapeutics for oncology,...
Cellino’s $80 Million Series A Financing
Wilson Sonsini Goodrich & Rosati advised Cellino on the deal. Cellino Biotech, an autonomous cell therapy manufacturing company, announced the completion of a Series A financing...
Best Buy’s Acquisition of Current Health
Wilson Sonsini Goodrich & Rosati and Taylor Wessing advised Current Health on the deal. Best Buy announced it had signed an agreement to acquire Current Health,...
AbSci’s Acquisition of Totient
Wilson Sonsini Goodrich & Rosati advised Totient on the deal. AbSci, the synthetic biology company unlocking the potential of proteins as next-generation therapeutics, announced the acquisition...
Arena Pharmaceuticals’ Strategic Collaboration with Aristea Therapeutics
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Arena Pharmaceuticals, Inc. and Aristea Therapeutics, Inc. announced a strategic collaboration to advance the clinical...
Aristea’s $63 Million Series B Financing Round
Wilson Sonsini Goodrich & Rosati advised Aristea Therapeutics on the deal. Aristea announced the closing of a $63 million Series B financing led by Fidelity Management &...
InSilico Medicine’s $255 Million Series C Financing
Wilson Sonsini Goodrich & Rosati advised InSilico Medicine on the deal. Ashurst represented Mirae Asset Capital. Hong Kong-based InSilico Medicine, a global leader in end-to-end artificial...
One Medical’s $2.1 Billion Acquisition of Iora Health
Skadden, Arps, Slate, Meagher & Flom advised Iora Health, while Cooley and Ropes & Gray advised One Medical on the deal. Wilson Sonsini Goodrich & Rosati...
Aerpio Pharmaceuticals’ Merger with Aadi Bioscience
Wilson Sonsini Goodrich & Rosati advised Aadi Bioscience on the deal while Goodwin Procter LLP represented Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals and Aadi Bioscience announced their...